Oxford Nanopore Technologies PLC
LSE:ONT

Watchlist Manager
Oxford Nanopore Technologies PLC Logo
Oxford Nanopore Technologies PLC
LSE:ONT
Watchlist
Price: 135.3 GBX 5.29% Market Closed
Market Cap: 1.3B GBX
Have any thoughts about
Oxford Nanopore Technologies PLC?
Write Note

Oxford Nanopore Technologies PLC
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Oxford Nanopore Technologies PLC
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Oxford Nanopore Technologies PLC
LSE:ONT
Total Liabilities & Equity
ÂŁ777.1m
CAGR 3-Years
40%
CAGR 5-Years
35%
CAGR 10-Years
N/A
Diaceutics PLC
LSE:DXRX
Total Liabilities & Equity
ÂŁ35.2m
CAGR 3-Years
-7%
CAGR 5-Years
35%
CAGR 10-Years
N/A
G
Genedrive PLC
LSE:GDR
Total Liabilities & Equity
ÂŁ3.4m
CAGR 3-Years
-20%
CAGR 5-Years
-18%
CAGR 10-Years
-13%
Ergomed PLC
LSE:ERGO
Total Liabilities & Equity
ÂŁ133.5m
CAGR 3-Years
16%
CAGR 5-Years
17%
CAGR 10-Years
N/A
C4X Discovery Holdings PLC
LSE:C4XD
Total Liabilities & Equity
ÂŁ26.2m
CAGR 3-Years
9%
CAGR 5-Years
13%
CAGR 10-Years
N/A
hVIVO PLC
LSE:HVO
Total Liabilities & Equity
ÂŁ87.7m
CAGR 3-Years
29%
CAGR 5-Years
41%
CAGR 10-Years
41%
No Stocks Found

Oxford Nanopore Technologies PLC
Glance View

Market Cap
1.2B GBX
Industry
Life Sciences Tools & Services

Oxford Nanopore Technologies PLC stands as a pioneering force in the field of genomics, transforming the landscape of DNA and RNA sequencing. Founded as a spin-off from the University of Oxford, the company gained recognition with its distinctive nanopore sequencing technology, which radically differs from traditional sequencing methods. Traditional sequencing often involves a process that can be expensive, time-consuming, and complex. However, Oxford Nanopore's approach uses tiny, porous apertures coupled with electrical signals to read genetic codes directly. This technology allows for the sequencing of long DNA strands in real-time, providing not only speed and efficiency but also the versatility to handle a wide range of samples, from environmental to clinical applications. By making sequencing more accessible and portable through their critically acclaimed MinION device, the company has managed to capture significant interest and investment from researchers across diverse scientific fields. The business model of Oxford Nanopore Technologies is built upon a strategic blend of product sales, including their sequencing devices and associated consumables, alongside providing commercial sequencing services. Their revenue streams are anchored by the MinION, GridION, and PromethION devices, each catering to varied throughput needs and scales of operation. Sales of these devices are complemented by a continuous income from consumable sales, essential for each sequencing run, which helps to embed their technology deeply within the workflows of their users. Additionally, the company's expansion into data analysis services further diversifies their income, utilizing their specialized expertise to assist customers in interpreting and utilizing complex genomic data. This multifaceted approach not only solidifies their position in the genomics market but also ensures multiple pathways for generating sustained revenue growth.

ONT Intrinsic Value
187.63 GBX
Undervaluation 28%
Intrinsic Value
Price

See Also

What is Oxford Nanopore Technologies PLC's Total Liabilities & Equity?
Total Liabilities & Equity
777.1m GBP

Based on the financial report for Dec 31, 2023, Oxford Nanopore Technologies PLC's Total Liabilities & Equity amounts to 777.1m GBP.

What is Oxford Nanopore Technologies PLC's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
35%

Over the last year, the Total Liabilities & Equity growth was -6%. The average annual Total Liabilities & Equity growth rates for Oxford Nanopore Technologies PLC have been 40% over the past three years , 35% over the past five years .

Back to Top